Fibroblast Growth Factor 23 Measurement in the Serum of Patients on Hemodialysis in Erbil Kidney Diseases and Dialysis Department

Majeed Hassan  Shekhany; Safa Ezzidin  Al Mukhtar

doi:10.56056/amj.2018.65

Authors

Majeed Hassan Shekhany MBChB, FIBMS (Internal Medicine). Lecturer, Internal Medicine, Kurdistan Board of Medical Specialties Erbil, Iraq.
Safa Ezzidin Al Mukhtar Consultant Nephrologist, Hawler Medical College, Erbil, Iraq

DOI:

https://doi.org/10.56056/amj.2018.65

Keywords:

Calcium, End stage renal disease, Fibroblast Growth Factor 23, Parathyroid hormone, Phosphate

Abstract

Background and objectives:Fibroblast growth factor 23 and para thyroid hormone in serum rise early during the course of chronic kidney disease in parallel with a decline in vitamin D. Elevations in fibroblast growth factor23 levels are one of the earliest manifestations of disordered bone-mineral metabolism in chronic kidney disease. Our aim was to assess the serum level of fibroblast growth factor23 among hemodialysis patients and comparing them with control group, and their relationships with parathyroid hormone, phosphate and calcium.

Methods: This is a case – control design where 80 patients of end stage renal disease on regular hemodialysis were enrolled. While the 80 control participants were relatives of the patients who had no medical illnesses. Serum calcium, phosphorus, parathyroid hormone, and fibroblast growth factor23 levels were measured for both groups.

Results: Diabetes mellitus was the most prevalent etiological factor for development of end stage renal disease (41.25%), hypertension was contributing to 23.75% of end stage renal disease cases. We found that whenever the value of parathyroid hormone, phosphate or calcium increase the level of fibroblast growth factor23 increases too, this increase was statistically significant and this finding was clear among all study samples including control group and also among patients group separately.

Conclusions: Sufficient hemodialysis has an important role in serum measures particularly parathyroid hormone, calcium, and phosphate and fibroblast growth factor 23.

Downloads

Download data is not yet available.

References

Tatsumi S. Regulation of renal phosphate handling: inter-organ communication in health and disease. J. Bone Miner Metab. 2016;34:1–10.

Wagner CA, Hernando N, Forster IC, Biber J. The SLC34 family of sodium- dependent phosphate transporters. Pflugers Archiv Eur J Physiology. 2014; 466:139–53.

Picard N, Capuano P, Stange G, et al. Acute parathyroid hormone differentially regulates renal brush border membrane phosphate cotransporters. Pflugers Arch Eur J Physiol. 2010;460: 677–87.

Sapir-Koren R, Livshits G. Bone mineralization is regulated by signaling cross talk between molecular factors of local and systemic origin: the role of fibroblast growth factor. Biofactors. 2014;40(6):555- 68.

Biber J, Hernando N. Forster I. Phosphate transporters and their function. Annu. Rev. Physiol. 2013;75:535–50.

Fernandes-freitas I. Owen BM. Metabolic roles of endocrine fibroblast growth factors. Science Direct. 2015;25:30–5.

Bhattacharyya N, Chong WH, Gafni, RI. Collins MT. Fibroblast growth factor23: state of the field and future directions. Trends Endocrinol. Metab. 2012;23:610.

Hu MC, Shiizaki K, Kuro-o M. Moe OW. Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism. Annu. Rev. Physiol. 2013;75:503–33.

Liu S. Quarles LD. How Fibroblast Growth Factor 23 Works. J. Am. Soc. Nephrol. 2007;18: 1637–47.

Quarles LD. Role of FGF23 in vitamin D and phosphate metabolism: implications in chronic kidney disease. Exp. Cell Res. 2012;318:1040.

van der Meijden K. van Essen HW, Bloemers FW, Schulten E, Lips P, Bravenboer N. Regulation of CYP27B1 mRNA Expression in Primary Human Osteoblasts. Calcif. Tissue Int. 2016; 99: 164–73.

Wolf M. White K. Coupling fibroblast growth factor 23 production and cleavage: iron deficiency, rickets, and kidney disease. Curr. Opin. Nephrol. Hypertens. 2014;23:411.

Guo YC. Yuan Q. Fibroblast growth factor 23 and bone mineralisation. Int. J. Oral Sci. 2015;7: 8–13.

Donate-Correa J, Muros-de-Fuentes M, Mora-Fernández C. Navarro-González J F. FGF23/Klotho axis: Phosphorus, mineral metabolism and beyond. Cytokine Growth Factor Rev. 2012;23:37–46.

Smith ER, McMahon LP. Holt SG. Fibroblast growth factor 23. Ann. Clin. Biochem. 2014;51:203–27.

Kovesdy CP. Quarles LD. Fibroblast growth factor-23: what we know, what we don’t know, and what we need to know. Nephrol. Dial. Transplant. 2013;28: 2228–36.

van Ballegooijen A J, Rhee EP, Elmariah S, de Boer IH. Kestenbaum,B. Renal Clearance of Mineral Metabolism Biomarkers. J. Am. Soc. Nephrol. 2016;27: 392–407.

Quarles L D. Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism. Nat. Rev. Endocrinol. 2012;8, 276–86.

Martin A, David V. Quarles LD. Regulation and function of the FGF23/ klotho endocrine pathways. Physiol. Rev. 2012;92:131–55.

Baum, M. The bone kidney axis. Curr. Opin. Pediatr. 2014;26:177–9.

Frassinetti Fernandes P, Ellis PA, Roderick PJ, Cairns HS. Causes of end-stage renal failure in black patients starting renal replacement therapy. Am J Kidney Dis.2000;36:301–9.

Young EW. An improved understanding of the causes of end-stage renal disease. Semin Nephrol. 1997;17(3):170-5.

Weber TJ, Liu S, Indridason OS, Quarles LD. Serum FGF23Levels in Normal and Disordered Phosphorus Homeostasis. J Bone Miner Res. 2003;18(7):1227-34.

Larsson T, Nisbeth U, Ljunggren O, Jüppner H, Jonsson KB. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int. 2003;64(6):2272-9.

Nakanishi S, Kazama JJ, Nii-Kono T, et al. Serum fibroblast growth factor- 23 levels predict the future refractory hyperparathyroidism in dialysis patients. Kidney Int. 2005;67:1171-8.

Kazama JJ, Sato F, Omori K, et al. Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients. Kidney Int. 2005;67:1120-5.

Melamed ML, Eustace JA, Plantinga L. et al. Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: A longitudinal study. Kidney Int. 2006; 70: 351-7.

Zaritsky J, Rastogi A, Fischmann G. et al. Short daily hemodialysis is associated with lower plasma FGF23 levels when compared with conventional hemodialysis. Nephrol Dial Transplant. 2014; 29: 437-41.